Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

  • STATUS
    Recruiting
  • End date
    Nov 18, 2023
  • participants needed
    78
  • sponsor
    Qurient Co., Ltd.
Updated on 26 February 2021

Summary

This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.

Details
Condition Metastasis, Liver Metastases, Bone Metastases, Solid Tumors, Solid Tumor, Advanced Cancer, Solid Neoplasm, Brain Metastases, Solid Tumour, Cancer, Metastatic, Metastatic Cancer, Neoplasm Metastasis, cancer advanced, cancers metastatic, metastases, metastatic disease, secondary cancer, secondaries, metastatic tumor, metastasized
Treatment Q702
Clinical Study IdentifierNCT04648254
SponsorQurient Co., Ltd.
Last Modified on26 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Advanced Cancer or Bone Metastases or Metastasis or Solid Tumour or Metastatic Cancer or Solid Tumors or Brain Metastases or metastases or metastatic ...?
Do you have any of these conditions: Liver Metastases or Solid Tumors or metastatic disease or Brain Metastases or cancer advanced or Bone Metastases or secondaries or Metastatic Cancer o...?
Do you have any of these conditions: Solid Tumors or Advanced Cancer or cancers metastatic or Bone Metastases or metastasized or secondaries or cancer advanced or Solid Tumor or Metastasi...?
Do you have any of these conditions: Advanced Cancer or metastatic disease or Liver Metastases or Solid Tumor or Solid Tumors or metastases or secondaries or metastatic tumor or metastasi...?
Do you have any of these conditions: metastasized or Solid Tumors or Solid Neoplasm or secondaries or Brain Metastases or Neoplasm Metastasis or cancer advanced or metastatic tumor or Bon...?
Do you have any of these conditions: Solid Neoplasm or secondaries or Solid Tumors or cancers metastatic or metastases or metastatic disease or Solid Tumor or Neoplasm Metastasis or Brain...?
Do you have any of these conditions: cancer advanced or Solid Tumors or Liver Metastases or Advanced Cancer or metastatic disease or secondaries or Solid Tumor or Solid Tumour or metastas...?
Do you have any of these conditions: Liver Metastases or Bone Metastases or Solid Tumor or Solid Tumors or Advanced Cancer or cancer advanced or metastatic tumor or Solid Tumour or Brain ...?
Patients with histologically or cytologically confirmed advanced or metastatic solid tumors, that have progressed following standard of care therapy or for which there is no standard therapy which confers clinical benefit
Measurable disease per RECIST v 1.1
ECOG performance status 0 or 1
Life expectancy of at least 3 months
Age 18 years
Signed, written IRB-approved informed consent form

Exclusion Criteria

New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months
Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec (females) and >450 msec (males)
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active, poorly controlled autoimmune or inflammatory diseases
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note